Navigation Links
Signaling pathway linked to inflammatory breast cancer may drive disease metastasis
Date:11/13/2011

SAN FRANCISCO Amplification of anaplastic lymphoma kinase, which has been reported in other cancers such as non-small cell lung cancers, may be a primary driver of the rapid metastasis that patients with inflammatory breast cancer experience.

If validated, the use of anaplastic lymphoma kinase (ALK) inhibitors may be a new treatment approach for patients with this lethal form of breast cancer.

These data were presented at the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, held Nov. 12-16, 2011.

"A diagnosis of inflammatory breast cancer carries with it a very low five-year survival rate of about 40 percent, clearly indicating the critical need for an understanding of the molecular basis of the disease," said Fredika M. Robertson, Ph.D., professor in the department of experimental therapeutics at The University of Texas M.D. Anderson Cancer Center and a member of the Morgan Welch Inflammatory Breast Cancer Research Program. "However, there are few molecules that have been identified that are matched with available targeted therapies of clinical benefit in patients with inflammatory breast cancer."

Robertson and colleagues used patient-derived tumors, tumor cell lines and animal models to evaluate protein-signaling pathways and genetic abnormalities with the goal of identifying molecules that may be associated with the increased metastases of inflammatory breast cancer. They discovered ALK amplification in 13 of 15 tumor samples taken from patients with this lethal variant of breast cancer. They then validated the presence of this abnormality in tumor cell lines and newly developed xenograft models.

Gene amplification of ALK is only found in about 2 percent of the overall breast cancer population, according to Robertson. However, results from this analysis indicate that in inflammatory breast cancer, it could be occurring in up to 86 percent of patients.

"The observation that ALK is amplified may be comparable to the observation of HER2 oncogene amplification in some cases of breast cancer, which revolutionized how the disease was treated," Robertson said. "Our observation that ALK is amplified in inflammatory breast cancer suggests that ALK may serve as a good target for treatment."

To test this, the researchers evaluated the effects of a drug that inhibits ALK using tumor cells isolated from patients with metastatic inflammatory breast cancer and in two animal models that recapitulate the disease. Results indicated that the use of this drug resulted in tumor cell death.

"Patients with inflammatory breast cancer are now being evaluated for ALK genetic abnormalities, and if found and eligible, may be enrolled in a phase 1, dose-escalation clinical trial of a small-molecule ALK/cMet inhibitor," Robertson said. She added that Massimo Cristofanilli, M.D., chair of medical oncology at Fox Chase Cancer Center in Philadelphia has implemented this trial at the center's Inflammatory Breast Cancer Clinic.

Moving forward, Robertson emphasized the importance of collaborating with a research team with expertise in using both proteomic and genomic approaches to define molecular biology of tumors, to identify therapeutic targets and, once validated, to rapidly translate these findings to the clinic.

"Our results demonstrate that, had we only been using genomic platforms, the likelihood of identifying ALK as a therapeutic target would have been significantly diminished," she said.


'/>"/>

Contact: Jeremy Moore
Jeremy.Moore@aacr.org
215-446-7109
American Association for Cancer Research
Source:Eurekalert

Related biology news :

1. New book on calcium signaling from Cold Spring Harbor Laboratory Press
2. Scripps Research scientists pinpoint shape-shifting mechanism critical to protein signaling
3. Molecular chaperones traffic signaling proteins between cells in plant stem-cell maintenance pathway
4. NYU Langone researchers identify a signaling pathway as possible target for cancer treatment
5. Animal model sheds light on rare genetic disorder, signaling pathway
6. Signaling pathway is executive software of airway stem cells
7. Study reveals important aspects of signaling across cell membranes in plants
8. Experimental drug inhibits cell signaling pathway and slows ovarian cancer growth
9. A new signaling pathway of the immune system is elucidated
10. Signaling path in brain may prevent that Im full message, UT Southwestern scientists discover
11. Nailing down a crucial plant signaling system
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2017)... , April 17, 2017 NXT-ID, Inc. ... company, announces the filing of its 2016 Annual Report on Form ... Exchange Commission. ... Form 10-K is available in the Investor Relations section of the ... on the SEC,s website at http://www.sec.gov . 2016 ...
(Date:4/11/2017)... , April 11, 2017 Crossmatch®, ... secure authentication solutions, today announced that it has ... Advanced Research Projects Activity (IARPA) to develop next-generation ... program. "Innovation has been a driving ... Thor program will allow us to innovate and ...
(Date:4/11/2017)... NXT-ID, Inc. (NASDAQ:   NXTD ) ("NXT-ID" or ... independent Directors Mr. Robin D. Richards and Mr. ... the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive Officer said," ... and benefiting from their considerable expertise as we move forward ...
Breaking Biology News(10 mins):
(Date:7/25/2017)... ... July 25, 2017 , ... ... of Strategic Planning. His extensive background in consulting, development and marketing make ... marketing and differentiation consulting, business strategy development, new product marketing and global ...
(Date:7/24/2017)... ... July 24, 2017 , ... ... announced that the stock market news outlet had initiated coverage on Interpace ... that screens and identifies exposure, progression and risk analysis from specific cancers ...
(Date:7/20/2017)... ... July 20, 2017 , ... VIC Technology Venture Development™ (VIC™), ... of directors. This addition continues to strengthen and diversify VIC’s board. , "We ... Chairman. “He is a highly accomplished business executive with a broad range of experience ...
(Date:7/18/2017)... ... July 18, 2017 , ... Nanomedical Diagnostics, a ... announces the launch of a new NTA biosensor chip for use with its ... the kinetics of polyhistidine-tagged (His-tagged) molecules quickly and reliably. , “Recombinant proteins ...
Breaking Biology Technology: